Skip to main content
Fig. 1 | Health Research Policy and Systems

Fig. 1

From: Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and development

Fig. 1

The 2016 Access to Medicine Index found that the 20 companies measured had 420 projects in development targeting the needs of people in low- and middle-income countries (LMICs). Of these, 36% of projects (151/420) targeted a research and development (R&D) priority and 30% (126/420) had access plans in place, two-thirds (67% or 85/126) of which also targeted an R&D priority. To drive the industry further to ensure populations in LMICs gain rapid access to the most-needed products, the 2018 Index will deepen analysis on both criteria [3]

Back to article page